Marta Llorens-Agost
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marta Llorens-Agost has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Markus Löbrich
Radiation Biology and DNA Repair, Technical University of Darmstadt, Darmstadt, Germany
4 shared publications - Michael Ensminger
Radiation Biology and DNA Repair, Technical University of Darmstadt, Darmstadt, Germany
4 shared publications Hang Phuong Le
Department of Microbiology and Molecular Genetics, University of California, Davis, Davis, CA, USA
3 shared publications- Wolf-Dietrich Heyer
University of California, Davis
3 shared publications - Andrés Cruz-García
Radiation Biology and DNA Repair, Technical University of Darmstadt, Darmstadt, Germany
2 shared publications Anugrah Gawai
Radiation Biology and DNA Repair, Technical University of Darmstadt, Darmstadt, Germany
2 shared publications
Latest Publications
- Open Access
- 28 March 2022
- Published by Springer Nature in BIOspektrum
- Vol. 28 (2) , 159-161
Reparaturwege in Krebszellen gezielt ausschalten
Mutations in BRCA1 or BRCA2 are associated with breast, ovarian and other cancers. Cells with these mutations are defective in homologous recombination (HR), one of two main processes to repair DNA double-strand breaks (DSBs). Survival of these cells strongly relies on the usage of alternative repair pathways, such as POLθ-mediated end-joining (TMEJ). Thus, targeting TMEJ could be a promising new strategy for the therapy of BRCA1- and BRCA2-mutant tumours.
- 28 March 2022
- Published by Springer Nature in BIOspektrum
- Vol. 28 (2) , 159-161
Open AccessReparaturwege in Krebszellen gezielt ausschalten
Mutations in BRCA1 or BRCA2 are associated with breast, ovarian and other cancers. Cells with these mutations are defective in homologous recombination (HR), one of two main processes to repair DNA double-strand breaks (DSBs). Survival of these cells strongly relies on the usage of alternative repair pathways, such as POLθ-mediated end-joining (TMEJ). Thus, targeting TMEJ could be a promising new strategy for the therapy of BRCA1- and BRCA2-mutant tumours.
- 2 November 2021
- Published by Taylor & Francis in Molecular & Cellular Oncology
- Vol. 8 (6) , 2007029
Turning end-joining upside down in mitosis
How cells deal with DNA breaks during mitosis is not well understood. While canonical non-homologous end-joining predominates in interphase, it is inhibited in mitosis to avoid telomere fusions. DNA polymerase θ mediated end-joining appears to be repressed in interphase, but promotes break repair in mitosis. The nature and induction time of breaks might determine their fate during mitosis.
- 2 November 2021
- Published by Taylor & Francis in Molecular & Cellular Oncology
- Vol. 8 (6) , 2007029
Turning end-joining upside down in mitosis
How cells deal with DNA breaks during mitosis is not well understood. While canonical non-homologous end-joining predominates in interphase, it is inhibited in mitosis to avoid telomere fusions. DNA polymerase θ mediated end-joining appears to be repressed in interphase, but promotes break repair in mitosis. The nature and induction time of breaks might determine their fate during mitosis.
- 27 October 2021
- Published by Springer Nature in Nature Cell Biology
- Vol. 24 (1) , 124
Publisher Correction: POLθ-mediated end joining is restricted by RAD52 and BRCA2 until the onset of mitosis
- 27 October 2021
- Published by Springer Nature in Nature Cell Biology
- Vol. 24 (1) , 124
Publisher Correction: POLθ-mediated end joining is restricted by RAD52 and BRCA2 until the onset of mitosis
- 6 October 2021
- Published by Springer Nature in Nature Cell Biology
- Vol. 23 (10) , 1095-1104
POLθ-mediated end joining is restricted by RAD52 and BRCA2 until the onset of mitosis
BRCA2-mutant cells are defective in homologous recombination, making them vulnerable to the inactivation of other pathways for the repair of DNA double-strand breaks (DSBs). This concept can be clinically exploited but is currently limited due to insufficient knowledge about how DSBs are repaired in the absence of BRCA2. We show that DNA polymerase θ (POLθ)-mediated end joining (TMEJ) repairs DSBs arising during the S phase in BRCA2-deficient cells only after the onset of the ensuing mitosis. This process is regulated by RAD52, whose loss causes the premature usage of TMEJ and the formation of chromosomal fusions. Purified RAD52 and BRCA2 proteins both block the DNA polymerase function of POLθ, suggesting a mechanism explaining their synthetic lethal relationships. We propose that the delay of TMEJ until mitosis ensures the conversion of originally one-ended DSBs into two-ended DSBs. Mitotic chromatin condensation might further serve to juxtapose correct break ends and limit chromosomal fusions.
- 6 October 2021
- Published by Springer Nature in Nature Cell Biology
- Vol. 23 (10) , 1095-1104
POLθ-mediated end joining is restricted by RAD52 and BRCA2 until the onset of mitosis
BRCA2-mutant cells are defective in homologous recombination, making them vulnerable to the inactivation of other pathways for the repair of DNA double-strand breaks (DSBs). This concept can be clinically exploited but is currently limited due to insufficient knowledge about how DSBs are repaired in the absence of BRCA2. We show that DNA polymerase θ (POLθ)-mediated end joining (TMEJ) repairs DSBs arising during the S phase in BRCA2-deficient cells only after the onset of the ensuing mitosis. This process is regulated by RAD52, whose loss causes the premature usage of TMEJ and the formation of chromosomal fusions. Purified RAD52 and BRCA2 proteins both block the DNA polymerase function of POLθ, suggesting a mechanism explaining their synthetic lethal relationships. We propose that the delay of TMEJ until mitosis ensures the conversion of originally one-ended DSBs into two-ended DSBs. Mitotic chromatin condensation might further serve to juxtapose correct break ends and limit chromosomal fusions.